Clinical Trial Update: Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating aldosterone breakthrough during Diovan, Tekturna, and combination therapy in proteinuric kidney disease was terminated with results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Nephropathy
• Focal Segmental Glomerulosclerosis
• Hypertensive Nephrosclerosis
• Iga Nephropathy
• Membranous Nephropathy
• Obesity-related Glomerulopathy
• Proteinuric Kidney Disease

Drugs mentioned

• DIOVAN (valsartan)
• Tekturna (aliskiren)

Snippet

Sponsor: Columbia University | Conditions: Proteinuric Kidney Disease, Diabetic Nephropathy | Phase 4 | Status: TERMINATED | Results posted: 2014-05-15